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Background
Antibody PG9 is a prototypical member of a class of
V1/V2-directed antibodies that effectively neutralizes
diverse strains of HIV-1. The crystal structure of PG9
bound to scaffolded V1/V2 has provided insight into its
mode of recognition. We sought to gain a more com-
plete understanding of the interaction of PG9 with the
functional viral spike, and to extend our understanding
to other antibodies of this class.
Methods
We analyzed amino acid frequencies in the V2 region of
PG9 sensitive and resistant strains to identify potentially
important residues. We also used the crystal structure
of PG9 with scaffolded V1/V2 to identify potential con-
tact sites. Based on these analyses we designed muta-
tions in PG9 resistant strains with the goal of “knocking
in” sensitivity. Parent and mutant Envs were used to
make pseudoviruses. The potency of PG9 as well as V1/
V2 antibodies PG16, CH01, CH04, PGT141, and
PGT145 against the pseudoviruses was assessed by
TZM-bl neutralization assay.
Results
For 20/20 of resistant strains, mutations in a short seg-
ment of V1/V2 resulted in gain of sensitivity to at least
one antibody of the PG9 class, and 13/20 showed gain
of sensitivity to 3 or more. Mutations in V2 strand C,
particularly the addition or substitution of lysine at posi-
tions 168, 169, or 171, had the greatest effects.
Conclusion
These results highlight the importance of strand C con-
tacts for neutralization by V1/V2 antibodies, provide
functional confirmation of the crystal structure, and sug-
gest a general mechanism of resistance to V1/V2-direc-
ted broadly neutralizing antibodies.
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